

**Multiple Myeloma Canada /
Myélome Multiple Canada
Financial Statements
For the year ended December 31, 2025**

Multiple Myeloma Canada / Myélome Multiple Canada
Financial Statements
For the year ended December 31, 2025

Contents

Independent Auditor's Report	3 - 5
Financial Statements	
Statement of Financial Position	6
Statement of Changes in Net Assets	7
Statement of Operations	8
Statement of Cash Flows	9
Notes to Financial Statements	10 - 15
Supplementary Financial Information	
Schedule of General and Administrative Expenditures	16

Independent Auditor's Report

To the board of directors of
Multiple Myeloma Canada / Myélome Multiple Canada

Qualified Opinion

We have audited the financial statements of Multiple Myeloma Canada / Myélome Multiple Canada, which comprise the statement of financial position as at December 31, 2025, and the statements of operations, changes in net assets and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of Multiple Myeloma Canada / Myélome Multiple Canada as at December 31, 2025, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Qualified Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Organization in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

In common with many charitable organizations, the Organization derives revenue from donations and cash receipts the completeness of which is not susceptible to satisfactory audit verification. Accordingly, our audit of these revenues was limited to the amounts recorded in the records of the Organization and we were not able to determine whether any adjustments might be necessary to revenues other than grants and investment income, deficiency of revenue over expenditures, and cash flows for the years ended December 31, 2025 and December 31, 2024 and assets and net assets as at December 31, 2025 and December 31, 2024.

Independent Auditor's Report

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Organization's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Organization or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Organization's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Independent Auditor's Report

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Organization's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Organization to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

1

BDO Canada s.r.l./S.E.N.C.R.L./LLP

Montréal, Québec
June 19, 2026

¹ CPA auditor, public accountancy permit No. A134347

Multiple Myeloma Canada / Myélome Multiple Canada

Statement of Financial Position

December 31	2025	2024
Assets		
Current		
Cash and cash equivalents	\$ 1,009,253	\$ 957,573
Contributions receivable	229	233,550
Sales taxes receivable	93,546	63,990
Prepaid expenditures	189,801	117,615
Investments (Note 2)	2,207,981	2,490,305
	<u>3,500,810</u>	<u>3,863,033</u>
Investments (Note 2)	946,264	544,347
Capital assets (Note 3)	20,001	19,704
Intangible asset (Note 4)	120,060	85,708
	<u>\$ 4,587,135</u>	<u>\$ 4,512,792</u>

Liabilities and Net Assets

Current		
Accounts payable and accrued liabilities (Note 5)	\$ 999,344	\$ 991,193
Deferred contributions (Note 6)	100,000	266,000
	<u>1,099,344</u>	<u>1,257,193</u>
Unrestricted net assets (Note 7)	<u>3,487,791</u>	<u>3,255,599</u>
	<u>\$ 4,587,135</u>	<u>\$ 4,512,792</u>

Commitments (Note 8)

On behalf of the Board:

 Director

 Director

Multiple Myeloma Canada / Myélome Multiple Canada

Statement of Changes in Net Assets

For the year ended December 31	2025	2024
Unrestricted net assets, beginning of the year	\$ 3,255,599	\$ 3,335,509
Excess (deficiency) of revenue over expenditures for the year	<u>232,192</u>	<u>(79,910)</u>
Unrestricted net assets, end of the year	<u>\$ 3,487,791</u>	<u>\$ 3,255,599</u>

Multiple Myeloma Canada / Myélome Multiple Canada Statement of Operations

For the year ended December 31	2025	2024
Revenue		
Industry grants	\$ 2,340,440	\$ 1,613,850
Fundraising events and donations	2,205,900	1,984,878
Estates	89,170	264,002
Other revenue	-	6,254
Investment income	102,164	155,059
Realized gain on disposal of investments	106,015	4,876
Unrealized gain on investments at fair value	66,154	75,547
	<u>4,909,843</u>	<u>4,104,466</u>
Expenditures		
Research	1,283,243	982,406
Fundraising	639,500	510,009
Patient and education programs	543,329	425,901
Awareness and communication	520,742	500,515
Community empowerment	519,489	645,120
Knowledge transfer	421,843	468,607
General and administrative (Schedule)	402,442	353,141
Governance	199,267	201,324
Access and advocacy	142,799	97,353
Other expenditures	4,997	-
	<u>4,677,651</u>	<u>4,184,376</u>
Excess (deficiency) of revenue over expenditures for the year	\$ 232,192	\$ (79,910)

The accompanying notes are an integral part of these financial statements.

Multiple Myeloma Canada / Myélome Multiple Canada

Statement of Cash Flows

For the year ended December 31	2025	2024
Cash flows from operating activities		
Excess (deficiency) of revenue over expenditures for the year	\$ 232,192	\$ (79,910)
Items not affecting cash		
Unrealized gain on disposal of investments	(106,015)	(4,876)
Unrealized gain on investments at fair value	(66,154)	(75,547)
Amortization of capital assets	7,551	9,192
Amortization of intangible asset	47,839	49,340
	<u>115,413</u>	<u>(101,801)</u>
Changes in non-cash working capital balances		
Contributions receivable	233,321	(141,250)
Sales taxes receivable	(29,556)	7,342
Prepaid expenditures	(72,186)	40,126
Accounts payable and accrued liabilities	8,151	(30,249)
Deferred contributions	(166,000)	103,280
	<u>89,143</u>	<u>(122,552)</u>
Cash flows from investing activities		
Purchase of investments	(3,200,866)	(1,860,320)
Proceed on disposal of investments	3,253,442	2,014,239
Purchase of capital assets	(7,848)	(5,151)
Purchase of intangible asset	(82,191)	-
	<u>(37,463)</u>	<u>148,768</u>
Net increase in cash and cash equivalents during the year	51,680	26,216
Cash and cash equivalents, beginning of the year	957,573	931,357
Cash and cash equivalents, end of the year	\$ 1,009,253	\$ 957,573

The accompanying notes are an integral part of these financial statements.

Multiple Myeloma Canada / Myélome Multiple Canada

Notes to Financial Statements

December 31, 2025

1. Significant Accounting Policies

Purpose of Organization Multiple Myeloma Canada / Myélome Multiple Canada is incorporated under the *Canada Not-for-profit Corporations Act* and is a registered charity under paragraph 149 (1) (f) of the *Income Tax Act*. Multiple Myeloma Canada / Myélome Multiple Canada is the only national organization exclusively devoted to the Canadian myeloma community. As a patient-driven, patient-focused organization, Multiple Myeloma Canada / Myélome Multiple Canada works with leading myeloma researchers and clinicians as well as other cancer organizations and local support groups across Canada, strengthening the voice of the Canadian myeloma community and improving the quality of life of myeloma patients, their caregivers and families through education, awareness, advocacy and research.

Basis of Accounting The financial statements have been prepared using Canadian accounting standards for not-for-profit organizations.

Revenue Recognition The Organization follows the deferral method of accounting for contributions. Restricted contributions are recognized as revenue in the year in which the related expenditures are incurred. Unrestricted contributions, if any, industry grants, fundraising events and donations, estates and other revenue are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Investment income is recognized when earned.

Government Assistance The policy of the Organization recognizes government assistance received or receivable to current expenditures for the year in revenue, if the amount to be received can be reasonably estimated and its collection is reasonably assured.

Contributed Services In the course of its activities, the Organization uses the services of volunteers as well as services and materials provided without monetary compensation. Given that the Organization does not pay for these services or materials and that it is impractical to estimate their fair value, they are not recognized in the financial statements.

Capital Assets Capital assets are stated at cost less accumulated amortization. Amortization based on the estimated useful lives of the assets is provided at the following annual periods:

	Method	Periods
Computer equipment	Declining balance	3 years
Furniture and fixtures	Declining balance	5 years
Building improvements	Straight-line	10 years

Multiple Myeloma Canada / Myélome Multiple Canada

Notes to Financial Statements

December 31, 2025

1. Significant Accounting Policies (continued)

Intangible Asset	Intangible asset is stated at cost less accumulated amortization. Amortization based on the estimated useful life of the asset is provided at the following annual periods:						
	<table><tr><th></th><th>Method</th><th>Period</th></tr><tr><td>Software</td><td>Declining balance</td><td>3 years</td></tr></table>		Method	Period	Software	Declining balance	3 years
	Method	Period					
Software	Declining balance	3 years					
Cash and Cash Equivalents	The policy of the Organization is to disclose bank balances under cash and cash equivalents, including bank overdrafts with balances that fluctuate frequently from being positive to overdrawn, and temporary investments with a maturity of three months or less from the date of acquisition.						
Foreign Currency Translation	Foreign currency accounts are translated into Canadian dollars as follows: At the transaction date, each asset, liability, revenue and expenditures is translated into Canadian dollars by the use of the exchange rate in effect at that date. At the year-end date, monetary assets and liabilities are translated into Canadian dollars by using the exchange rate in effect at that date. The resulting foreign exchange gains and losses are included in income in the current period.						
Financial Instruments	Arm's length financial instruments are recorded at fair value at initial recognition. Related party financial instruments quoted in an active market or those with observable inputs significant to the determination of fair value or derivative contracts are recorded at fair value at initial recognition. All other related party financial instruments are recorded at cost at initial recognition. In subsequent periods, equities traded in an active market and derivatives are reported at fair value, with any change in fair value reported in income. All other financial instruments are reported at cost or amortized cost less impairment. Transaction costs on the acquisition, sale or issue of financial instruments are expensed for those items measured at fair value and charged to the financial instrument for those measured at amortized cost.						

Multiple Myeloma Canada / Myélome Multiple Canada

Notes to Financial Statements

December 31, 2025

1. Significant Accounting Policies (continued)

Financial Instruments (continued)	Financial assets are tested for impairment when indicators of impairment exist. When a significant change in the expected timing or amount of the future cash flows of the financial asset is identified, the carrying amount of the financial asset is reduced and the amount of the write-down is recognized in net income. A previously recognized impairment loss may be reversed to the extent of the improvement, provided it is not greater than the amount that would have been reported at the date of the reversal had the impairment not been recognized previously, and the amount of the reversal is recognized in net income.
Allocation of Expenditures	The Organization engages in various programs related to their purpose as set out above. The cost of each program includes the costs of personnel that are directly related to providing these programs. The allocation is based on the time devoted to each program.

2. Investments

The carrying amounts of investments are comprised of the following:

	2025	2024
Marketable securities at cost	\$ 2,962,578	\$ 2,914,286
Changes in fair value	191,667	120,366
Marketable securities at fair value	3,154,245	3,034,652
Less: marketable securities only redeemable after January 1, 2027 (cost - \$945,772, 2024 - \$544,057)	946,264	544,347
Marketable securities at fair value (cost - \$2,016,806, 2024 - \$2,370,229) in current assets	<u>\$ 2,207,981</u>	<u>\$ 2,490,305</u>

Multiple Myeloma Canada / Myélome Multiple Canada

Notes to Financial Statements

December 31, 2025

3. Capital Assets

	2025		2024	
	Cost	Accumulated Amortization	Cost	Accumulated Amortization
Computer equipment	\$ 65,906	\$ 48,477	\$ 58,417	\$ 43,119
Furniture and fixtures	16,971	14,399	17,489	13,787
Building improvements	3,018	3,018	3,018	2,314
	85,895	65,894	78,924	59,220
Net book value		\$ 20,001		\$ 19,704

4. Intangible Asset

	2025		2024	
	Cost	Accumulated Amortization	Cost	Accumulated Amortization
Software	\$ 485,326	\$ 365,266	\$ 403,124	\$ 317,416
Net book value		\$ 120,060		\$ 85,708

5. Accounts Payable and Accrued Liabilities

	2025	2024
Accounts payable and accrued liabilities	\$ 923,520	\$ 940,837
Salaries and vacation payable	75,824	50,356
	\$ 999,344	\$ 991,193

Multiple Myeloma Canada / Myélome Multiple Canada

Notes to Financial Statements

December 31, 2025

6. Deferred Contributions

The following summarizes the changes in deferred contributions related to projects carried out in the current year:

	2025	2024
Balance, beginning of the year	\$ 266,000	\$ 162,720
Deferred contributions received during the year	100,000	266,000
Less: amount recognized in revenue in the year	(266,000)	(162,720)
Balance, end of the year	<u>\$ 100,000</u>	<u>\$ 266,000</u>

7. External and Internal Restrictions on Net Assets

In 2022, the Organization's board of directors internally restricted \$750,000 of unrestricted net assets to be held for wind-up purposes and not available for distribution of operations. These internally restricted amounts are not available for other purposes without approval of the board of directors. No changes were made to these internally restricted funds in 2025.

8. Commitments

The Organization has entered into a real estate lease agreement for its premises until March 2027 with future minimum lease payments for the next two years as follows:

2026	\$ 21,463
2027	<u>5,366</u>
	<u>\$ 26,829</u>

Multiple Myeloma Canada / Myélome Multiple Canada

Notes to Financial Statements

December 31, 2025

9. Risks Arising from Financial Instruments

The Organization is exposed to various risks by virtue of holding financial instruments. There have been no changes to the Organization's exposure to those risks nor in how those risks are managed since the previous year.

Currency risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

The Organization is exposed to currency risk in foreign currency rates resulting from U.S. dollar cash and cash equivalents. At December 31, 2025, cash denominated in U.S. dollars expressed in Canadian dollars was \$40,167 (2024 - \$41,783).

Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Organization is exposed to credit risk with respect to cash and cash equivalents and investments from the potential default by counterparties that carry the Organization's cash and cash equivalents and investments. The Organization mitigates the credit risk by dealing with only large financial institutions with good credit ratings. The Organization is also exposed to credit risk arising from its contributions receivable. The Organization works to ensure that the receivables meet all eligibility criteria in order to qualify to receive the funding.

Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. The Organization is subject to liquidity risk on its accounts payable which arise from its daily operations. The Organization manages this risk by monitoring working capital and cash flows needs. In February 2022, Multiple Myeloma Canada adopted a resolution to restrict \$750,000 in order to limit this risk.

Other price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. The Organization is exposed to price risk from its investment portfolio. The Organization moderates this risk through the selection and diversification of securities held within the portfolio.

Multiple Myeloma Canada / Myélome Multiple Canada
Schedule of General and Administrative Expenditures

For the year ended December 31	2025	2024
Rent	\$ 71,895	\$ 88,736
Salaries	97,187	85,752
Traveling	54,107	37,704
Insurance	28,704	28,196
Bank and credit card fees	31,759	27,916
Stationery, postage and telephone	37,817	26,797
Accounting and legal	29,074	25,878
License and memberships	35,625	17,873
Amortization of capital and intangible assets	7,146	8,895
Repairs and maintenance	7,933	3,621
Professional services	1,195	1,773
	\$ 402,442	\$ 353,141
